Shares of Roivant Sciences were higher in afternoon trading after Bloomberg’s Michelle Davis and Dinesh Nair reported that the company is attracting interest from large pharmaceutical companies for its treatment of inflammatory bowel disease, RVT-3101, which could be worth more than $7B. People familiar with the matter told the reporters that while deliberations have focused on the treatment, which is being tested to treat ulcerative colitis and Crohn’s disease, it is possible the entire company could be sold as well, according to the report. In afternoon trading, Roivant shares are up 29c, or 3%, to $10.92.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant Sciences should be bought on recent weakness, says Citi
- Roivant Sciences price target raised to $18 from $15 at H.C. Wainwright
- UPDATE — Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- Roivant Sciences expects cash to fund operations into 2H25
- Roivant Sciences announces upcoming milestones